Zhou Liu

Mr. Zhou Liu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Cellular Signalling
Verified
Journal Article
Closed access
TYTao Yan
Tao Yan
MLMin Li
Min Li
QWQiuyan Wang
Qiuyan Wang
MWMeng Wang
Meng Wang
LLLijuan Liu
Lijuan Liu
ZGZhen Gong
Zhen Gong

1 February 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
TYTao Yan
Tao Yan
QWQiuyan Wang
Qiuyan Wang
CMChengcheng Ma
Chengcheng Ma
XTXuan Teng
Xuan Teng
ZGZhen Gong
Zhen Gong
ZLZhou Liu
Zhou Liu
Purpose: Klebsiella pneumoniae is a globally prevalent pathogen responsible for severe hospital- and community-acquired infections, and presents significant challenges for clinical management. Current therapeutic strategies are no longer able to meet the clinical needs; therefore, there is an urgent need to develop novel therapeutic strategies. This study aimed to evaluate the efficacy of phage therapy in treating bacterial infections. Methods: Isolated phage vB_Kpn_HF0522 and phage morphology were observed using transmission electron microscopy. Analysis of vB_Kpn_HF0522 characteristics, including optimal multiplicity of infection (MOI), one-step growth curve, host range, stability in different environments, and adsorption capacity. The phage genomic sequence was analyzed to explore evolutionary relationships. The effect of phage vB_Kpn_HF0522 on biofilms was assessed using crystal violet staining assay. The Galleria mellonella (G. mellonella) infection model and mouse infection models were established to evaluate the practical application potential of the phage and the fitness cost of phage-resistant bacteria. Results: Phage was isolated from hospital sewage for experimental studies. Genome analysis revealed that vB_Kpn_HF0522 is a double-stranded linear DNA virus. Biological characterization demonstrated that this phage specifically targets serotype K1 K. pneumoniae with an optimal multiplicity of infection (MOI) of 0.01, effectively disrupting biofilms and inhibiting bacterial growth. The bacterial growth rate remained largely unchanged after the phage resistance mutation, but mice infected with the mutant strain showed significantly higher survival rates than those infected with the wild-type strain. vB_Kpn_HF0522 increased the survival rate of infected G. mellonella from 12.5% to 75%, inhibited incisional surgical site infections and alleviated inflammatory response in mice. Conclusion: These findings indicate that vB_Kpn_HF0522 has significant potential for treating specific bacterial infections, and may serve as an antimicrobial agent for research and clinical anti-infective therapy.

1 February 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
QWQiuyan Wang
Qiuyan Wang
TYTao Yan
Tao Yan
CMChengcheng Ma
Chengcheng Ma
XTXuan Teng
Xuan Teng
CSChengyin Shen
Chengyin Shen
ZLZhou Liu
Zhou Liu
Purpose: This study aims to investigate the relationship between glycemic control and epidemiological characteristics of patients infected with carbapenem-resistant Klebsiella pneumoniae (CRKP), to identify mortality risk factors associated with CRKP infection, and to evaluate the impact of glucose on the resistance of CRKP to polymyxin and serum killing. Patients and Methods: Clinical cases of 218 patients infected with CRKP were collected from a large tertiary public hospital in Anhui Province. We analyzed whether the glycemic control impacts the clinical and laboratory manifestations of infected patients. Logistic regression identified mortality risk factors. Antibiotic sensitivity, capsular serotypes, and virulence genes were tested of the strains. Three clinically isolated CRKP strains were used to investigate the effect of glucose on bacterial capsule synthesis and the impact on bacterial resistance to polymyxin and serum killing. Results: Patients with poor glycemic control experienced more severe infections and had a higher likelihood of chronic kidney disease (CKD) and acute renal insufficiency compared to those with good glycemic control. They also exhibited an increased mortality rate. Logistic regression analysis identified age, glycosylated hemoglobin (HbA1c) ≥ 7%, CKD, tumor, mechanical ventilation, and sepsis as independent risk factors for death associated with CRKP infection. A 0.5% (0.5 g/100mL) glucose environment can stimulate CRKP capsule synthesis, which is inhibitable by cyclic adenosine monophosphate (cAMP). Moreover, a high-glucose environment can enhance CRKP’s resistance to polymyxin and serum killing. Conclusion: A persistent hyperglycemic environment resulting from poor glycemic control may stimulate the synthesis of CRKP capsules, which could enhance the resistance of CRKP to polymyxin and serum killing, thereby further increasing the risk of patient mortality.